Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Valneva ( (VALN) ) has shared an announcement.
On June 26, 2025, Valneva SE announced an exclusive agreement with CSL Seqirus for the marketing and distribution of its three proprietary vaccines in Germany. This agreement will see CSL Seqirus commercialize Valneva’s chikungunya vaccine IXCHIQ® starting July 2025, and its Japanese Encephalitis vaccine IXIARO® and cholera/ETEC1 vaccine DUKORAL® from January 2026. The new partnership replaces a previous agreement with Bavarian Nordic and is set to last for three years, including minimum annual purchasing quantities. This collaboration is expected to enhance Valneva’s commercial presence in Europe’s largest travel vaccine market, complementing its existing infrastructure and potentially driving significant growth in product sales, which are projected to reach €170-180 million in 2025.
The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects financial challenges with persistent losses and negative cash flows, which are the most significant factors. Technical analysis further indicates a bearish trend. Despite strong revenue growth and potential future regulatory successes, the current valuation and profitability concerns weigh heavily on the stock’s attractiveness. The earnings call provides some optimism but is overshadowed by the immediate financial and operational hurdles.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in developing vaccine candidates for Lyme disease, Shigella, Zika virus, and other public health threats.
Average Trading Volume: 77,226
Technical Sentiment Signal: Sell
Current Market Cap: $466.7M
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.